Ace Vision Group, Inc.(AVG) was established in 2006 as a medical device company developing eye laser technology and natural therapeutic procedures to treat age-related eye dysfunction.
AVG establishes Taiwan partnership with Vision ReNu Taiwan Corporation for R&D, clinical trials and development of the company's technology including manufacturing of surgical...
AVG in collaboration with Vision ReNu and Emergo Group Jytong successfully complete regulatory submissions to both Taiwan FDA and China FDA approval for its laser and procedure.
AVG selects the Chang Gung Memorial Hospital in Taipei, Taiwan as its Institutional partner to conduct the world's first LaserACE® procedure IRB registered clinical trials.
AVG receives Taiwan FDA approval in October of 2011 and China FDA approval in December of 2011. Vision ReNu becomes significant shareholder in Ace Vision Group. AVG raised $2.1M through Taiwan...
AVG launches its first IRB registered Clinical Trial in Taipei Taiwan in March of 2012 and first LaserACE® procedure in the world is performed by Dr. David HK Ma, MD, PhD in March 2012.
AVG completes its enrolment of the Taiwan clinical trial and presents its 1 year data at major ophthalmology world congresses.
AVG files an uber patent in March 2014 on behalf of its future technology device development efforts.
AVG receives a $75,000 Grant from the SNEC to conduct its wound healing studies scheduled to begin in June of 2015.